Clover Biopharmaceuticals Launches COVID-19 Booster Vaccine in the People's Republic of China
SHANGHAI - Clover Biopharmaceuticals, Ltd. , a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the... Clover Biopharmaceuticals (Clover) has launched its COVID-19 booster vaccine in the People's Republic of China, a recombinant SARS-CoV-2 subunit vaccine. The vaccine is part of a national second booster dose (fourth vaccination dose) campaign targeting older adults, immunocompromised individuals and individuals with comorbidities (LINK). In a global Phase 2/3 clinical trial with over 30,000 participants across five countries, it achieved 100% efficacy against severe COVID 19 and hospitalization caused by all strains of SARS CoV2 circulating during the trial. In addition to province, Clover has started launch preparation activities in multiple strategically prioritized provinces and municipalities where it expects additional launches in Q1 2023.
Được phát hành : 2 năm trước qua MarketScreener trong Health Finance
- (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in has begun with the first doses delivered and administered in Changxing, as part of national second booster dose (fourth vaccination dose) campaign targeting older adults, immunocompromised individuals and individuals with comorbidities (LINK).
'We are very proud to be delivering on our commitment to help protect the elderly and other vulnerable populations with our premium COVID-19 booster vaccine, and commencing the launch in province where our vaccine is manufactured,' said , Chief Executive Officer and Executive Director of Clover. 'I would like to sincerely thank everyone who contributed to making today's launch possible, including our employees, clinical trial investigators and participants, health authorities in and around the world, and our CEPI partners who provided instrumental technical and funding support.'
Clover's COVID-19 vaccine was authorized for emergency use in in . Subsequently, the formally announced its national immunization plan for a second booster dose campaign and recommended prioritizing specified vaccines that demonstrate broad neutralization against Omicron, including Clover's, for use.
'CEPI's significant early investments in Clover's COVID-19 vaccine have accelerated the clinical development and manufacturing of the vaccine and will enable equitable access to doses to millions of vulnerable people in and the rest of the world,' said Dr. , Executive Director of Vaccine R&D at CEPI. 'As a result of CEPI's partnership with Clover, this vaccine is poised to play a significant role in protecting those most at risk from COVID-19 as part of the international community's ongoing management of SARS-CoV-2.'
In a global Phase 2/3 clinical trial with over 30,000 participants across five countries, Clover's COVID-19 vaccine achieved 100% efficacy against severe COVID-19 and hospitalization caused by all strains of SARS-CoV-2 circulating during the trial (LINK). In addition, a study embedded within this Phase 2/3 trial demonstrated that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received Clover's vaccine, compared to households where the infected household member was not vaccinated (LINK). Finally, in a separate Phase 3 study, Clover's COVID-19 vaccine demonstrated broad and robust cross-neutralization of multiple Omicron subvariants, including Omicron BA.1, BA.2, and BA.5, when it was administered as a third dose heterologous booster after two doses of inactivated vaccine-a response that was superior to a third dose of inactivated vaccine (LINK) (LINK). Analysis of the booster vaccine's cross-neutralization of more recently circulating subvariants including Omicron BF.7, BQ.1.1 and BA.2.75 is consistent with prior data.
In addition to province, Clover has started launch preparation activities in multiple strategically prioritized provinces and municipalities where it expects additional launches in Q1 2023. Further expansion within will continue through 2023 based on production capacity and market dynamics. Outside of , Clover is also prioritizing additional regulatory submissions directly in select countries, primarily in and , based on the potential to generate significant near-term revenue and impact via bilateral supply agreements.
is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases-and to make more diseases preventable.
This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'going forward,' 'intend,' 'may,' 'might,' 'ought to,' 'plan,' 'potential,' 'predict,' 'project,' 'seek,' 'should,' 'will,' 'would' and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.
Chủ đề: Coronavirus, Markets, China